This study, based on a multicentric cohort of CML patients with durable DMR (≥2 years), shows that the dPCR appears to be more accurate and sensitive than conventional RT‐qPCR for detecting and monitoring the BCR‐ABL1 molecular levels. The gene discussed is BCR; the disease is chronic myelogenous leukemia, BCR-ABL1 positive.